Related Experiment Videos
Treatment perspectives in hypertension
1Istituto di Clinica Medica e Terapia Medica, Università di Milano, Italy.
Insights
Traditional hypertension trials focus on cardiovascular events, potentially underestimating benefits in mild cases. New methods assessing organ damage offer a more comprehensive evaluation of antihypertension therapy effectiveness.
Area of Science:
- Cardiology
- Clinical Trials
- Hypertension Research
Background:
- Current hypertension treatment benefit assessment relies on cardiovascular event monitoring.
- This approach has limitations in evaluating underlying vascular injury mechanisms and treatment efficacy in diverse patient groups.
Purpose of the Study:
- To highlight the limitations of event-based trials in hypertension research.
- To advocate for incorporating organ damage monitoring in hypertension trials.
- To emphasize the need for distinct evaluation criteria for preventing cardiovascular events versus organ damage.
Main Methods:
- Critique of existing event-based randomized trials in hypertension.
- Discussion of the feasibility of organ damage monitoring using new quantitative techniques.
- Conceptual framework for evaluating antihypertension therapy.
Main Results:
- Event-based trials may underestimate antihypertension therapy benefits, particularly in younger patients with mild hypertension.
- Organ damage monitoring provides a more sensitive measure of treatment benefit in these populations.
- New techniques make organ damage assessment feasible in clinical trials.
Conclusions:
- Antihypertension therapy has dual goals: preventing cardiovascular events and preventing organ damage.
- Separate trial methodologies and criteria are necessary to evaluate these distinct goals.
- Integrating organ damage assessment will improve the understanding of treatment benefits in hypertension.
Abstract:
Despite the considerable progress in our understanding of the mechanisms of hypertension-related cardiovascular damage, assessment of treatment benefit is so far based on randomized trials monitoring cardiovascular events only. There are inherent limitations to this approach. First, the mechanisms precipitating events are partly different from mechanisms leading to the underlying vascular injury, and evidence obtained on therapeutic prevention of events cannot be automatically applied to therapeutic prevention of disease. Second, event-based trials are suitable to test treatment effectiveness only in those conditions, such as severe hypertension and hypertension in the elderly, in which a high rate of events is expected during the necessarily short duration of the trials. Third, in young and middle-aged patients with mild hypertension, event-based trials are likely to have markedly underestimated treatment benefits. Fourth, in these patients the benefits of antihypertension therapy can be better explored by trials monitoring the progress of organ damage than by trials monitoring the occurrence of events. Finally, trials monitoring organ damage are now feasible as new quantitative, sensitive, and reliable techniques are available. Both prevention of cardiovascular events and prevention of organ damage and disease are essential goals of antihypertension therapy, and achievement of these two distinct goals has to be evaluated through trials using different types of criteria.